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http://dx.doi.org/10.1016/j.ccr.2013.01.025SUMMARYThe molecular mechanisms regulating leukemia-initiating cell (LIC) function are of important clinical signifi-
cance. We use chronic myelogenous leukemia (CML) as a model of LIC-dependent malignancy and identify
the interaction between the ubiquitin ligase Fbw7 and its substrate c-Myc as a regulator of LIC homeostasis.
Deletion of Fbw7 leads to c-Myc overexpression, p53-dependent LIC-specific apoptosis, and the eventual
inhibition of tumor progression. A decrease of either c-Myc protein levels or attenuation of the p53 response
rescues LIC activity and disease progression. Further experiments showed that Fbw7 expression is required
for survival and maintenance of human CML LIC. These studies identify a ubiquitin ligase:substrate pair
regulating LIC activity, suggesting that targeting of the Fbw7:c-Myc axis is an attractive therapy target in
refractory CML.INTRODUCTION
Chronic myeloid leukemia (CML) was the first type of cancer
for which a specific chromosomal abnormality was identified—
the Philadelphia chromosome (Nowell and Hungerford, 1960).
Subsequent studies identified that the translocation event
occurred between t(9;22)(q34;q11), which fused the breakpoint
cluster region gene (BCR) with the Abelson kinase gene (ABL1)
to produce the BCR-ABL oncogene (Bartram et al., 1983; Row-
ley, 1973). This Bcr-Abl fusion protein possesses constitutive
tyrosine kinase activity resulting in development of myeloid leu-
kemia through aberrant differentiation of hematopoietic stemSignificance
CML is initiated by the BCR-ABL translocation and maintaine
they are insufficient to target LIC. Utilizing a Bcr-Abl model o
E3 ligase Fbw7 is required for the initiation and progression o
that interaction between Fbw7 and its protein substrate c-My
to p53-mediated apoptosis of LIC. In agreement with these fi
self-renewal. These studies identify Fbw7 ligase as an essent
targeting Fbw7 activity in CML.
362 Cancer Cell 23, 362–375, March 18, 2013 ª2013 Elsevier Inc.cells (HSC) toward the myeloid lineage. CML is dependent on
Bcr-Abl-induced c-Myc expression (Sawyers et al., 1992). Clini-
cally, CML progresses through at least three different phases:
a chronic phase (CP), a late chronic/accelerated phase (AP),
and a blast crisis (BC).
Patients diagnosed with CML in the early CP have been
successfully treated with tyrosine kinase inhibitors (TKIs), such
as imatinib, that inhibit the tyrosine kinase activity of Bcr-Abl
and have a 5-year progression-free survival rate of 89% (Druker
et al., 2006). However, only a fraction of TKI-treated patients
achieve long-term remission, suggesting that the compound is
unable to target CML-initiating cells (de Lavallade et al., 2008;d by LIC. Although current therapies can suppress disease,
f CML and human CML samples, we demonstrate that the
f CML as well as maintenance of the LIC. We demonstrate
c is required for CML progression, and Fbw7 deletion leads
ndings, silencing of FBW7 leads to loss of human CML LIC
ial regulator of CML LIC maintenance and open the way for
AC
B
101 102 103
Bcr-Abl
# 
of
 C
el
ls
101 102 103
Bcr-Abl
# 
of
 C
el
ls
Control
Fbw7–/–
10
50
30
70
C
FU
 (A
vg
)
*
Control
* *
D
40 60
20
40
60
80
100
0
0
S
ur
vi
va
l (
%
)
Time(days)
20
Control
Fbw7–/– 
80 100
p<0.01
Fbw7–/–
Fbw7–/–
20 μm
Control
20 μm
Fbw7
Control
24% 1%
Figure 1. Fbw7 Deletion Suppresses Initia-
tion of Bcr-Abl-Induced CML
(A) Average CFU from VavCre+;Fbw7+/+ and
VavCre+;Fbw7/ cells infected with Bcr-Abl-ex-
pressing retrovirus at the first plating. Images on
right are representative colonies from control or
Fbw7/ Bcr-Abl+ LSKs. Scale bar, 100 mm.
(B and C) FACS analysis (B) and blood smears (C)
of PB taken from host mice transplanted with
VavCre+;Fbw7+/+ (Control) or VavCre+;Fbw7/
Bcr-Abl+ LSK cells.
(D) Kaplan Meier survival curves of irradiated
animals that were transplanted with VavCre+;
Fbw7+/+ or VavCre+;Fbw7/Bcr-Abl+ LSKs. (n = 5
for each genotype). Error bars indicate ± SD.
***p < 0.0001.
See also Figure S1.
Cancer Cell
Fbw7 Controls CML-Initiating Cell MaintenanceHochhaus et al., 2009). Indeed, the majority of the patients expe-
rience relapse upon cessation of treatment (Michor et al., 2005).
Moreover, resistance to imatinib treatment can develop in some
patients, particularly those who present with advanced disease
(O’Hare et al., 2006). The mechanisms thought to drive resis-
tance and disease relapse include the acquisition of mutations
in the kinase domain of Bcr-Abl, amplification of BCR-ABL,
and clonal evolution (Gorre et al., 2001; le Coutre et al., 2000;
Shah et al., 2002).
An increasing body of work has suggested that disease
relapse upon cessation of TKI therapy could be due to a rare
population of leukemia-initiating cells (LICs) that are resistant
or refractory to treatment (Bhatia et al., 2003; Corbin et al.,
2011; Jankowska et al., 2009). LICs are thought to possess
properties similar to normal HSC such as self-renewal, quies-
cence, and resistance to traditional chemotherapy (Bonnet
and Dick, 1997; Huntly and Gilliland, 2005). Thus, the LIC
subset might act as a reservoir contributing to relapse by
passing BCR-ABL on to its progeny. In different types of
leukemia, evidence in support of the LIC determined that
only a small fraction of acute myeloid leukemia cells from
patients were able to recapitulate the disease when trans-
planted into immunocompromised animals (Bonnet and Dick,
1997; Lapidot et al., 1994). Using similar assays, putative LIC
populations were also identified in patients diagnosed with CP
and BC CML (Jamieson et al., 2004; Sirard et al., 1996; Wang
et al., 1998).
The development of disease animal models, which proved that
expression of Bcr-Abl is indeed leukemogenic, provided an im-
portant tool to investigate themechanisms involved in LICmainte-
nance (Daley et al., 1990; Heisterkamp et al., 1990; Pear et al.,
1998). Over the years, Bcr-Abl has been shown to contribute to
tumorigenesis through deregulation of molecular pathways that
control HSC self-renewal and differentiation (Heidel et al., 2012;
Zhaoetal., 2007,2009).Moreover, transplantationstudies inmouse
models of Bcr-Abl-induced CP CML suggested that LIC activity
is confined to Bcr-Abl-expressing Lineage (Lin)Sca1+c-Kit+Cancer Cell 23, 362–37(LSK) cells, which contain the HSC popu-
lation (Neering et al., 2007).
Fbw7 is an E3 ubiquitin ligase and is a
substrate recognition component of theCullin-1/SCF complex that targets specific substrate proteins
for poly-ubiquitination and degradation by the 26S proteasome.
Fbw7 has been shown to regulate a number of oncoproteins
such as c-Myc, Notch, and cyclinE (Gupta-Rossi et al., 2001;
Koepp et al., 2001; Welcker et al., 2004; Yada et al., 2004). More-
over, we and others have shown that Fbw7 is essential for the
maintenance of adult HSC quiescence (Matsuoka et al., 2008;
Thompson et al., 2008). Indeed, deletion of Fbw7 in HSC leads
to c-Myc accumulation, aberrant cell cycle entry, and eventual
HSC exhaustion (Reavie et al., 2010). Here, we explore the role
of the Fbw7:c-Myc axis and relative abundance of c-Myc protein
in the maintenance of CML LIC.
RESULTS
Fbw7 Deletion Suppresses Initiation of Bcr-Abl-
Induced CML
To address the role of Fbw7 in the self-renewal and differentia-
tion of LIC, we used a well-established animal model of Bcr-
Abl-induced CP CML (Pear et al., 1998). In this model, Bcr-
Abl-expressing retroviruses are used to infect highly-purified
hematopoietic stem and progenitor cells, LSK. Transduced
LSKs are then transplanted into lethally irradiated recipients,
which develop a CML-like disease that is characterized by the
accumulation of Bcr-Abl+CD11b+Gr1+ cells in the peripheral
blood (PB), splenomegaly, and tissue infiltration. The pathology
of the disease replicates the CP of CML due to less than 2% of
the mononuclear population in the PB has blast morphology,
a hallmark of disease progression, whereas the majority dis-
plays morphology consistent with mature myeloid cells. Mice
succumb to disease starting at25–30 days posttransplantation
(Figure 1 and data not shown). To initially test the role of Fbw7
function in CML in vitro, we used a conditional Fbw7 allele
(Vav1cre+;Fbw7f/f) that specifically targets deletion in hemato-
poietic cells, starting from the HSC subset during development,
and purified LSK cells from 2- to 4-week-old mice (before any
significant alterations of the LSK compartment are evident)5, March 18, 2013 ª2013 Elsevier Inc. 363
Cancer Cell
Fbw7 Controls CML-Initiating Cell Maintenance(Matsuoka et al., 2008; Stadtfeld and Graf, 2005; Thompson
et al., 2007, 2008). Fbw7/ and Fbw7+/+ LSK cells were infected
with Bcr-Abl retroviruses, sorted by flow cytometry for Bcr-Abl+,
and plated on colony-forming unit (CFU) assays. Control (Bcr-
Abl+;Fbw7+/+) LSK cells generated colonies at the first plating
and were able to serially replate demonstrating extensive prolif-
eration potential (Figure 1A and data not shown). Interestingly,
Bcr-Abl+;Fbw7/ LSK cells generated only a few small colonies
at the first plating and were unable to replate, suggesting direct
effects of Fbw7 deletion on survival of the cells. This was an
unexpected finding, as WT (Bcr-Abl) Fbw7/ LSK cells are
able to efficiently generate colonies at the first plating, and
their colony-forming ability is only progressively lost (Figure S1
available online), suggesting distinct responses to Fbw7 deletion
between physiologic and leukemic LSK cells (Thompson et al.,
2008). To address Fbw7 function in CML in vivo, LSKs were
infected with Bcr-Abl-expressing retroviruses and transplanted
into lethally irradiated recipient mice. Control Bcr-Abl-express-
ing cells were able to initiate disease and progress to lethal
CML (Figures 1B–1D). On the other hand, Bcr-Abl-expressing
Fbw7/ LSK cells were unable to initiate disease and recipient
animals did not develop CML (Figures 1B–1D). These effects
on the initiation of CML were not a consequence of Fbw7
deletion on HSC homing and engraftment, suggesting a direct
role on the maintenance of Bcr-Abl+ cells (Figure S1; data not
shown). These data suggest that Fbw7 deletion inhibits Bcr-
Abl induction of CML due to direct effects on Bcr-Abl+ LSK cell
maintenance.
Fbw7 Deletion Suppress Bcr-Abl-Induced Disease
Progression
The above experiments address the effects of Fbw7 on transfor-
mation but do not study its role during progression ofCML in vivo.
To experimentally address this questionwe took advantage of an
inducible Fbw7 allele and crossed these mice to the Mx1cre
strain, of which Cre-recombinase is expressed as early as the
HSC stage upon administration of poly(I:C) (Mx1cre+;Fbw7f/f)
and allows for gene deletion after the onset of the disease. In
these experiments, CMLwas established by Bcr-Abl-expressing
Mx1cre+;Fbw7f/f and littermate control LSK cells. Disease onset
was verified by flow cytometry 7 days posttransplantation (Fig-
ure 2A). Fbw7 deletion was achieved by three poly(I:C) injections
and confirmed by quantitative reverse transcriptase PCR (qRT-
PCR) analysis (Figure 2B). Notably, tumor LSKs expressed the
highest levels of Fbw7 when compared to more differentiated
subsets (Figure 2B). Control recipients developed CML as char-
acterized by the accumulation of Bcr-Abl+CD11b+Gr1+ cells in
the bone marrow (BM) (Figure 2C), PB (Figures 2A and 2D),
and peripheral organs such as the spleen, liver, and lung
(Figure 2E and data not shown). In contrast, poly(I:C)-mediated
deletion of Fbw7 led to a rapid reversal of CML progression
(as judged by both Bcr-Abl+ and CD11b+ absolute cell numbers,
Figures 2A and 2C), resulting in almost no infiltration of
secondary tissues by leukemic cells (Figure 2E). More impor-
tantly, while all control mice succumbed to the disease by day
50 posttransplantation, the majority of recipient animals trans-
planted with Bcr-Abl+;Mx1cre+;Fbw7f/f cells and injected with
poly(I:C) survived (Figure 2F). These studies demonstrated that
Fbw7 deletion suppresses further development of CML and364 Cancer Cell 23, 362–375, March 18, 2013 ª2013 Elsevier Inc.leads to disease remission, suggesting effects on putative
leukemia-initiating cells.
Fbw7-Deficient Bcr-Abl Cells Have No Leukemia-
Initiating Activity In Vivo
To directly test the self-renewal capacity of the LIC fraction,
we performed secondary transplantation experiments using
whole spleen cells isolated 10 days after poly(I:C)-treatment
from Mx1cre+;Fbw7/ and littermate controls. To ensure that
identical numbers of Bcr-Abl+ LSKs were transplanted in both
cohorts, we normalized the total number of spleen cells based
on the frequency of Bcr-Abl+ LSK cells. In agreement with our
previous findings, recipients of Fbw7/ tumor cells did not
develop CML (Figure S2). In contrast, control Bcr-Abl+ cells
harbored LIC activity when transplanted into secondary recipi-
ents and transferred disease exhibiting the same hallmarks as
the primary CML (Figure S2). These results strongly suggested
that Fbw7 deletion specifically inhibits CML LIC activity.
Fbw7 Deletion Affects Survival of CML-Initiating Cell
Populations
It was previously shown that the LIC activity in Bcr-Abl-induced
CML is confined to the Linc-Kit+ and specifically the LSK subset
of the Bcr-Abl-expressing tumor (Neering et al., 2007). To
directly study putative effects of Fbw7 deletion in these subsets,
we studied both their relative representation and their absolute
numbers in response to Fbw7 deletion (using the inducible
Mx1cre+;Fbw7f/f in vivo model). Fbw7 deletion in established
CML led to the rapid and significant loss of Bcr-Abl+ Lin-c-Kit+
and more specifically the Bcr-Abl+ LSK population (Figure 3A).
Interestingly, at the same time points, we were able to detect
more differentiated Bcr-Abl-expressing tumor cells, suggesting
that deletion of Fbw7 specifically targets immature LIC subsets
(Figure 2C). The acute loss of Bcr-Abl+ LSK cells following
Fbw7 deletion was significantly more rapid than what has been
reported for WT LSK cells, which takes 3–4 months (Matsuoka
et al., 2008; Thompson et al., 2008). QRT-PCR studies showed
that CML LSK cells express slightly higher levels of Fbw7
mRNA than WT LSK but the difference is not statistically signifi-
cant (Figure S1D). To identify a putative mechanism to explain
the impact of Fbw7 deletion on the Bcr-Abl+ LSK population,
we evaluated apoptosis and cell death using Annexin-V and
7AAD. As shown in Figure 3B, Fbw7 deletion led to a rapid and
significant increase (5- to 8-fold) in the fraction of the Bcr-Abl+
LSK cells undergoing apoptosis, suggesting direct induction of
cell death in this stem and progenitor subset. We further evalu-
ated p53 pathway target genes associated with cell survival by
qRT-PCR and found Puma, Bax, p21, and Noxa upregulated in
Fbw7/ tumor LSKs (Figure 3C and data not shown), sug-
gesting that p53 pathway activation mediates the induced death
of Fbw7-deficient Bcr-Abl+ LSK cells. These studies provide
the biologic mechanism explaining the loss of Bcr-Abl+ LICs
and the suppression of disease progression in response to
Fbw7 deletion.
c-Myc Is the Key Substrate Targeted by Fbw7
in CML-Initiating Cell Populations
As we have previously shown that c-Myc is an Fbw7 substrate
during early hematopoiesis (Reavie et al., 2010) and CML is
Figure 2. Fbw7 Is Essential for Progression of Established CML In Vivo
(A) PB frommice transplanted withMxCre+;Fbw7+/+ andMxCre+;Fbw7/Bcr-Abl infected LSK cells. The bar graph on right is a quantification of Bcr-Abl+ cells in
the PB.
(B) qRT-PCR analysis of Fbw7 expression in sorted populations from WT and Fbw7/ CML 5 days after the post-poly(I:C) injection.
(C) FACS analysis of the BM of animals transplanted with Bcr-Abl+ LSK cells.
(D) Blood smears 10 days post-poly(I:C) injections.
(E) Hematoxylin and eosin (H&E) staining of liver and lung.
(F) Kaplan Meier survival curves of irradiated animals that were transplanted with Fbw7+/+ or Fbw7/ Bcr-Abl+ LSKs. (n = 9 for each genotype). Error bars
indicate ±SD. *p < 0.01, **p < 0.001.
See also Figure S2.
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Figure 3. Fbw7 Deletion Affects CML-Initiating Cell Survival through the Activation of the p53 Pathway
(A) FACS plots depicting the relative percentage of Bcr-Abl expressing stem and progenitor (LSK), and progenitors (Linc-Kit+Sca) cells in the BM of
MxCre+;Fbw7+/+ orMxCre+;Fbw7/ mice. Bar graphs depict the number of tumor stem and progenitor cells based on the frequency of LSK in total number of
BM cells.
(B) FACS plots showing relative annexin V and 7-AA-positive cells in the Bcr-Abl+ LSK subset in the BM. Graph on right represents percent of annexin V+ cells in
the Bcr-Abl+ LSK.
(C) qRT-PCR analysis showing expression of the p53 target genes, Puma, Bax, and p21, in sorted control or Fbw7/ LSKs from the tumor. Error bars indicate ±
SD (n = 4 for each genotype). *p < 0.05, **p < 0.01.
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Fbw7 Controls CML-Initiating Cell Maintenancedependent on c-Myc induced by Bcr-Abl (Sawyers et al., 1992),
we investigated the possibility that unphysiologically high levels
of the oncogenic c-Myc protein could cause the cell death
observed upon loss of Fbw7 expression in CML. We further
hypothesized that this was most likely through activation of the
p53 pathway since p53 target genes were upregulated in
Fbw7/ Bcr-Abl+ LSKs (Figure 3C). Because we have shown
differential effects of Fbw7 deletion on WT and Bcr-Abl+ LSK
function in vitro (Figures 1 and S1), we directly compared levels
of c-Myc protein in these two subsets using a targeted c-Myc
allele that expresses a c-Myc-eGFP fusion protein (c-MyceGFP),
which has been shown to be a functional protein fusion and
a faithful indicator of endogenous c-Myc protein levels (Huang
et al., 2008). Despite the fact that c-Myc mRNA levels were
unchanged between control and Fbw7-deficient Bcr-Abl+ LSKs
(Figure 4A), using this allele (Mx1cre+;Fbw7f/f;c-MyceGFP/+), we
showed that Bcr-Abl+ LSK cells expressed significantly higher
c-Myc protein levels than WT LSK cells (Figure 4B). These data
were further corroborated by western blot (Figure 4C). Notably,
c-Myc protein levels were higher in leukemic LSKs when com-
pared to both WT LSK and Fbw7/ LSKs, explaining the366 Cancer Cell 23, 362–375, March 18, 2013 ª2013 Elsevier Inc.different physiologic responses observed between nonleukemic
and leukemic LSKs in response to Fbw7 deletion (Figure 4C). In
Bcr-Abl+ LSK cells, loss of Fbw7 expression further induced the
levels of c-Myc protein beyond that observed in WT leukemic
LSK cells (Figure 4D). These observations suggested that slight
changes in c-Myc protein abundance could result in distinct
phenotypic responses.
Additional Fbw7 substrates, particularly Notch, have been
previously implicated in CML progression (Ito et al., 2010) and
could influence the observed LIC defects upon Fbw7 deletion
in Bcr-Abl+ LSKs. To address this question, we initially evaluated
the expression level of cleaved Notch1 in WT and Fbw7/ Bcr-
Abl+ c-Kit+ cells. Expression of Notch1was not detected in either
population (Figure S3A). Of note, Notch1 and Notch2 do not
appear to be important Fbw7 substrates in WT HSCs because
generation of triple knockout mice (MxCre+;Fbw7f/f;Notch1f/f;
Notch2f/f) could not rescue the HSC defects observed in
Fbw7/LSKs (nonleukemic) (Figures S3B–S3E). More spe-
cifically, the frequency (total cell number) of CD150+ CD48
LSKs and aberrant cell cycle status were unaffected by reduc-
ing Notch levels in Fbw7-deficient mice (Figures S3B–S3D;
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Figure 4. Decrease of c-Myc Protein Levels and Inhibition of p53 Activation Rescue CML-Initiating Activity
(A) qRT-PCR analysis of c-Myc expression in sorted tumor subsets (LSK, c-Kit+, and Lin+).
(B) c-Myc protein expression in normal and Bcr-Abl+ LSK cells in the BM. Graph on right shows mean fluorescence intensity (MFI) for eGFP (c-Myc protein).
(C) Western blot analysis of c-Myc protein expression in LSKs sorted from WT tumor, Fbw7/ and WT mice.
(D) c-Myc protein expression in MxCre+;Fbw7+/+ or MxCre+;Fbw7/ Bcr-Abl+ LSK.
(E) Average CFU from sorted Bcr-Abl+ LSK cells from MxCre+;Fbw7+/+, MxCre+;Fbw7/, or MxCre+;Fbw7/;Myc+/ mice.
(F andG) Average CFU from sorted Bcr-Abl+ LSK cells fromMxCre+;Fbw7+/+,MxCre+;Fbw7/, MxCre+;Fbw7/;shp53, orMxCre+;Fbw7/;p53/mice on the
first (F) and secondary (G) platings.
(H) Images of Bcr-Abl+ colonies generated from the indicated genotypes (n = 3 for each genotype). Scale bar 100 mm.
(I) Kaplan Meier survival curves of animals transplanted with control (red), Fbw7/;Myc+/ (blue) LSKs transduced with a retrovirus expressing Bcr-Abl, or
Fbw7/ LSKs transduced with a retrovirus expressing Bcr-Abl and a shRNA targeting p53 (green). Error bars indicate ± SD. *p < 0.01, **p < 0.001.
See also Figure S3.
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Cancer Cell
Fbw7 Controls CML-Initiating Cell MaintenanceThompson et al., 2008 and unpublished). These in vivo studies
have defined the effects of Fbw7 on leukemia-initiating cell pop-
ulations. They have also demonstrated that c-Myc (and not
Notch1/2) is the major Fbw7 substrate in CML. However, we
cannot exclude that other Fbw7 substrates may play a part in
the regulation of CML LIC.
Decrease of c-Myc Protein Levels and p53 Silencing
Rescues Fbw7–/– LIC Function
To directly address the mechanisms of action of Fbw7 in CML-
initiating cells, we attempted to genetically rescue Fbw7 deletion
effects on the survival of the Bcr-Abl+ LSK population. We gener-
ated Mx1cre+;Fbw7f/f;c-Mycf/+ mice and silenced p53 expres-
sion in Mx1cre+;Fbw7f/f cells by using a p53-specific shRNA
or by deleting p53, Mx1cre+;Fbw7f/f;p53/ mice (Bric et al.,
2009). We hypothesized that a decrease in c-Myc protein levels
or the inhibition of p53 response could rescue the ability of
Fbw7/ Bcr-Abl+LSK cells to maintain CML disease progres-
sion in vivo and serially replate in vitro. As shown in Figures
4E–4I, both genetic modifications led to a significant rescue of
the ability of the Fbw7-deficient LSK cells to generate colonies
in vitro and to induce disease in vivo. The Fbw7/;c-Myc/+,
Fbw7/;shp53 and Fbw7/;p53/ colonies were almost in-
distinguishable in numbers from colonies generated by WT
cells and no lineage differences were noted (Figures 4E–4H).
Fbw7/;c-Myc/+ and Fbw7/;p53/ colonies were able to
serially replate in a fashion identical to WT counterparts (Fig-
ure 4G). To directly assess the self-renewal ability of LICs,
we transplanted transduced LSKs from Fbw7/;c-Myc/+ or
Fbw7/;shp53 into lethally irradiated recipients. Importantly,
mice receiving Bcr-Abl+ LSKs from Fbw7/;c-Myc/+ devel-
oped a CML-like disease with similar kinetics to Bcr-Abl+ control
cells restoring Fbw7/LIC self-renewal capacity (Figure 4I).
However, as previously shown by Lowe and colleagues, loss of
p53 in CML leads to disease progression, and Bcr-Abl+ shp53+
LSKs from Fbw7/ progressed to an AP based on pathology
and 5% blasts in the periphery (data not shown) (Wendel
et al., 2006). These experiments demonstrate that c-Myc overex-
pression and p53-mediated cell death are responsible for the
apoptotic phenotype of the Fbw7-deficient LIC.
In Vivo Visualization of c-Myc Protein Expression in CML
These studies suggested that CML-initiating cells express
c-Myc protein and depend on its activity. Although it was previ-
ously shown that Bcr-Abl induces the transcription of c-Myc (Na-
kamura et al., 2012; Xie et al., 2002), it is unclear whether c-Myc
function is essential for the initiation and/or the progression of
the disease in vivo. To address this question, we utilized the
c-MyceGFP genetic model and visualized c-Myc expression in
established CML. As shown in Figure 5A, only a minority of
CML (Bcr-Abl+) cells express detectable levels of c-Myc protein.
All c-Myc protein expression is confined within the Lin fraction
and comprises approximately 10%–20% of the bulk of the
tumor. Myc protein expression was detected in both Bcr-Abl+
Lin c-Kit+ and Bcr-Abl+ LSK populations. In contrast, Bcr-Abl+
CD11b+Gr1+ cells are negative for GFP expression (Figure 5A).
To test whether there is a correlation between leukemia-initiating
activity and c-Myc protein expression, identical numbers of puri-
fied different tumor subsets were transplanted into secondary368 Cancer Cell 23, 362–375, March 18, 2013 ª2013 Elsevier Inc.recipients. Neither the Lin+ c-Myc/eGFP nor the Lin c-Myc/
eGFP fractions were able to transfer disease (Figure S4 and
data not shown). On the other hand, all leukemia-initiating
activity was confined to the c-MyceGFP leukemic cell fraction
(Figures S4B andS4C). However, flow-cytometry-based separa-
tion of Bcr-Abl+Linc-Kit+Sca1 and Bcr-Abl+ Linc-Kit+Sca1+
fractions, coupled to subsequent transplantation experiments,
demonstrated that only the LSK fraction could transfer disease
in secondary hosts (Figures S4B and S4C). This finding contrasts
with c-Myc protein expression and function in normal LSK cells,
where two distinct populations exist. The c-Myc population
contains HSC activity and a c-Myc+ population containsmultipo-
tential progenitors (Reavie et al., 2010). These studies demon-
strate in vivo c-Myc visualization in leukemia and suggest that
although LIC activity lies within the c-Myc-expressing fraction,
c-Myc protein expression is not sufficient to guarantee leukemia
initiation.
Bcr-Abl-Induced CML Is Addicted to c-Myc Expression
and Function
To test the importance of c-Myc protein expression in CML
initiation and progression, we used a conditional c-Myc allele
(Mx1cre+;c-Mycf/f). All genotypes prior to deletion were able to
initiate disease as verified by PB analysis (Figure 5B). Once
disease onset was verified, c-Myc was deleted using poly(I:C)
administration. Deletion of c-Myc led to an almost complete
absence of Bcr-Abl+ cells from PB and infiltration in secondary
tissues such as liver and lung within 3 weeks (Figures 5B and
5C). Mice carrying c-Myc/ Bcr-Abl+ cells were followed up to
6–8 months posttransplantation and never developed any signs
of a CML-like disease. On the other hand, control mice carrying
Mx1cre+;c-Myc+/+ Bcr-Abl+ cells succumbed to a lethal CML-
like disease within 5 weeks posttransplantation (Figure 5D).
To further quantify c-Myc protein levels, we utilized mice
carrying only one allele of c-Myc (Mx1cre+;c-Mycf/w). We had
previously shown that these LSK cells express lower levels of
c-Myc protein (Reavie et al., 2010). Bcr-Abl+c-Myc+/ LSK cells
were able to generate colonies in vitro, at similiar efficiency
to their Bcr-Abl+c-Myc+/+ counterparts in both primary and
secondary platings (Figure S4D). We then initiated disease by
transplanting Bcr-Abl-expressing LSK (Bcr-Abl+c-Myc+/) cells
and upon verification of CML initiation, deleted one c-Myc allele
by poly(I:C) administration. Interestingly, a single allele of c-Myc
was sufficient to maintain disease progression (Figures S4E–
S4G). These studies suggest that there are well-defined thresh-
olds of c-Myc protein expression, which is controlled by
Fbw7-mediated ubiquitination, essential for CML induction and
progression. Indeed, both are lacking and nonphysiologically
increased levels of c-Myc severely affect CML progression.
Fbw7 Deletion Inhibits Progression of Established,
Bcr-Abl-Induced B-Cell Acute Lymphoblastic Leukemia
The BCR-ABL translocation is also found in B cell acute lympho-
blastic leukemia (B-ALL). We thus determined whether Fbw7
plays a role in progression of B-ALL. To establish B-ALL, we
transduced MxCre+;Fbw7+/+ or MxCre+;Fbw7f/f whole BM with
retrovirus expressing Bcr-Abl-GFP followed by transplanta-
tion into lethally irradiated recipient mice. PB was analyzed
12 days posttransplantation to determine initiation of disease
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See also Figure S4.
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Fbw7 Controls CML-Initiating Cell Maintenanceby Bcr-Abl+B220+. Both cohorts of mice showed approximately
40% Bcr-Abl+B220+ cells. At that point, deletion of Fbw7 was
initiated by administration of poly(I:C) (Figure 6A) and disease
progression was monitored. As expected, mice transplanted
with Bcr-Abl+MxCre+;Fbw7+/+ BM had an increase in the per-
centage of Bcr-Abl+B220+ cells in the PB. However, mice
transplanted with Bcr-Abl+ MxCre+;Fbw7f/f BM showed a sig-
nificant reduction in Bcr-Abl+B220+ cells (Figure 6A) and these
cells were virtually undetectable 3 weeks after the initiation
of Fbw7 deletion (Figure 6B). MxCre+;Fbw7+/+ mice showed
signs of B-ALL including infiltration of secondary tissues and
splenomegaly, whereas mice transplanted with MxCre+;Fbw7f/f
showed no sign of disease following treatment with poly(I:C)
(Figures 6C–6E). Once more, utilizing the c-MyceGFP mouse
model, we evaluated c-Myc protein expression in the tumor todetermine whether loss of B-ALL was due to stabilization of
c-Myc as seen in the CML model. Unlike the CML model,
approximately 100% of Bcr-Abl+ cells were B220+ and Bcr-
Abl+ LSKs were not observed. Although a significantly greater
percentage of the tumor in Fbw7/ expressed c-MyceGFP, no
overall increase in expression was observed suggesting that
Fbw7 could have additional substrates in B-ALL (Figures 6F
and 6G). Analysis of Annexin V and 7-AAD in the Bcr-Abl+
B220+ BM cells showed a significant increase in cell apoptosis
and cell death along with induction of apoptosis-associated
p53 targets in MxCre+;Fbw7/ BM (Figures 6H and 6I). This is
an exciting finding because it suggests that Fbw7 could be an
attractive therapeutic target in Bcr-Abl+ B-ALL. In agreement
with this notion, sequencing of FBW7 in the cDNA of patients
with B-ALL failed to identify any inactivating mutations (0/50Cancer Cell 23, 362–375, March 18, 2013 ª2013 Elsevier Inc. 369
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Figure 7. FBW7 and c-MYC Expression
Patterns in Human CML
(A and B) FBW7 and c-MYC mRNA levels (A,
determined by qRT-PCR, bar indicates average)
and c-Myc protein levels (B, determined by
western blot) from total PBMNCs in healthy indi-
viduals (normal), CML patients in CP without
treatment (CP) or being treated with Imatinib
(CP Tx), or in BC (BC).
(C) qRT-PCR for c-MYC and FBW7 mRNA levels
from CD34+CD38+ and CD34+CD38low pop-
ulations from BM of patients in CP, and BC nor-
malized to normal UCB derived CD34+CD38low.
Bar indicates average.
(D) FACS plots showing CD45 and CD34 ex-
pression in human CML patients used to sort
CD34+CD38+ andCD34+CD38low cell populations.
*p < 0.01, **p < 0.001.
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Fbw7 Controls CML-Initiating Cell Maintenancesamples), suggesting that FBW7 function is required for B-ALL
disease progression (data not shown).
Human CML Leukemia-Initiating Cells Require FBW7
Function
Depletion of Fbw7 in the mouse model eradicates the CML LIC;
we next asked whether these findings are relevant to the human
disease. Consistent with the findings that Bcr-Abl induces
c-MYC expression (Xie et al., 2002), we observed that c-MYC
expression level in PB mononuclear cells (PBMNCs) of patients
is higher in patients with newly diagnosed or untreated CP
CML than in normal PBMNC. Patients with TKI-treated CML
CP displayed almost physiologic levels of c-MYC (Figure 7A).
c-Myc protein levels followed similar patterns of expression (Fig-
ure 7B). On the other hand, no significant differences in the levels
of FBW7 expression were noted (Figure 7A), consistent with the
idea that FBW7 is also controlled at the activity level and not
merely transcriptionally.
We further determined the levels of c-MYC and FBW7 expres-
sion in stem and progenitor populations in patients with CML by
sorting CD34+CD38+ and CD34+CD38low populations, respec-
tively, from CP, and patient BC BM samples (Figures 7C and
7D). c-MYC mRNA expression was detected in all subsets;
however, its highest level was in BC CD34+CD38low cells. Inter-
estingly, although FBW7 was also expressed in all samples, CP
CD34+CD38low cells expressed significantly higher levels than
CD34+CD38+ cells from the same samples, in agreement with
our animal modeling data that detected the highest Fbw7
expression in the LSK LIC population.
To address whether Fbw7 possesses a similar functional role
in human CML, we transduced the Bcr-Abl+ human CML cell line
KU812with lentiviruses expressing shRNAs against Fbw7. Effi-
cient knockdown was confirmed by qRT-PCR (Figure S5A).
Loss of Fbw7 induced apoptosis and lead to the accumulation
of c-Myc (Figures S5B and S5C). Degradation of c-Myc requires
a priming phosphorylation event on T58 by GSK3b (Gregory
et al., 2003), and in agreement with this, Fbw7 silencing lead to
the specific enrichment of phosphorylated c-Myc (Figure S5C).
To further study potential Fbw7 functions in human cells, we first
silenced Fbw7 using lentiviruses expressing shRNAs againstFbw7 in normal umbilical cord blood (UCB)-derived CD34+
with or without co-infection with Bcr-Abl retrovirus and subse-
quently plated the cells in colony-forming assays. Fbw7 silencing
showed no alterations in the colony-forming ability of normal
CD34+ cells, but significantly decreased plating capacity of
Bcr-Abl+ CD34+ cells (Figures 8A and 8B). Fbw7 silencing led
to accumulation of both c-Myc and phospo-c-Myc protein in
total progeny derived from Bcr-Abl+-infected CD34+ cells (Fig-
ure 8C). Overexpression of c-Myc protein was further verified
in the Bcr-Abl+ CD34+ population compared to normal CD34+
population by intracellular FACS for c-Myc expression. Consis-
tent with the finding in the mouse model, Bcr-Abl expression
results in increased c-Myc expression, which is further increased
by silencing of Fbw7 (Figure 8D). Finally, FBW7 silencing in
purified primary human CP (from either newly diagnosed or
untreated patients) CML CD34+ cells led to a significant loss of
plating ability in CFU assays (Figures 8E, S5D, and S5E), most
likely due to the elevated levels of c-Myc, and significant induc-
tion of cell death (Figures 8F, 8G, and S5F). These combined
human data are in agreement with our animal experiments.
DISCUSSION
We demonstrate here the essential function of the Fbw7 E3
ligase for the initiation and the progression of CML. Fbw7 dele-
tion leads to LIC apoptosis due to aberrantly high levels of
c-Myc protein expression and activation of the p53 pathway.
Interestingly, p53 mutations can accompany disease progres-
sion in human CML and p53 loss in some cases impedes
the antileukemic response to Bcr-Abl inhibition (Kelman et al.,
1989; Wendel et al., 2006), suggesting that loss of p53 in some
tumors could constitute an adaptive response to the increase
in the levels of c-Myc during CML progression. Overall, our
experiments suggest that Fbw7 expression is absolutely essen-
tial for themaintenance of nontoxic levels of c-Myc protein within
CML LIC cells. Interestingly, although Fbw7 is a ubiquitin ligase
capable of targeting a large number of substrates, our results
suggest that c-Myc is its key substrate in CML, in contrast with
human T-ALL, where Notch1 appears to be a main targets
(O’Neil et al., 2007; Thompson et al., 2008). However, we cannotCancer Cell 23, 362–375, March 18, 2013 ª2013 Elsevier Inc. 371
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Figure 8. Fbw7 Silencing in Human
CML-Initiating Cells Leads to Induction
of Apoptosis and Loss of Differentiation
Potential
(A) Average CFU from normal UCB derived CD34+
cells expressing shRNA against either NonTarget
or Fbw7.
(B–D) Normal UCB-derived CD34+-expressing
Bcr-Abl together with shRNAs against either
NonTarget or Fbw7. Progeny of cells were plated
in CFU assay (B; scale bar, 200 mm) and western
blot for c-Myc, Phospho-c-Myc, and Bcr-Abl in
total progeny of CD34+ cells (C). c-Myc expression
determined by intracellular FACS gated on CD34+
population (D). Graph on right shows MFI for
c-Myc protein.
(E–G) CP patient BM derived CD34+ cells were
transduced with lentivirus expressing either con-
trol or shRNAs against Fbw7, puromycin selected
for 48 hr. Average CFU assay fromCD34+ progeny
in two different patients (E). MFI for c-Myc protein
for representative CML patient derived CD34+
cells following Fbw7 silencing (F). Representative
annexin V staining of patient derived CD34+ cells
following lentiviral transduction (G). Error bars
indicate ± SD. *p < 0.01, **p < 0.001.
See also Figure S5.
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Fbw7 Controls CML-Initiating Cell Maintenanceexclude that additional Fbw7 substrates, except for Notch1, play
roles in its function. Further studies are required to address the
identity and function of such substrates.
Wewere able to visualize, using flow cytometry, c-Myc protein
abundance in vivo, and show that c-Myc expression is restricted
within the LIC population, with the bulk of the tumor being
c-Myc. These results prove that Fbw7 function is specifically
required by cells with leukemia-initiating activity but is dis-
pensable for the maintenance of the more differentiated CML
subset. Moreover, genetic deletion of c-Myc during disease
progression showed that Bcr-Abl-driven CML is addicted to
physiologic c-Myc function, suggesting that the disease requires
well-defined and Fbw7-regulated thresholds of c-Myc abun-
dance and activity. This is an intriguing idea with potential
important clinical ramifications in the field of cancer biology, as
it would suggest that both depletion and overabundance of
c-Myc protein levels in tumors could lead to similar clinical
outcomes, albeit with distinct mechanisms of action. Recent
development of small molecules targeting c-Myc co-activator
bromodomain inhibitors (Delmore et al., 2011) opens the way
for therapeutic protocols that include c-Myc activity inhibition
in established CML.
Classic experiments have shown that introduction of v-abl in
a myeloid cell line can specifically induce c-Myc expression in
a tyrosine kinase-dependent manner (Cleveland et al., 1989).
Subsequent seminal studies by Sawyers and colleagues demon-372 Cancer Cell 23, 362–375, March 18, 2013 ª2013 Elsevier Inc.strated that Bcr-Abl-induced transforma-
tion could be suppressed by dominant
negative Myc mutants in vitro (Sawyers
et al., 1992). In agreement with these
studies, we visualized c-Myc protein
levels in vivo in progressing CML andidentify the populations that retain c-Myc protein expression.
Interestingly, only a minority of the established leukemia cells
express c-MyceGFP. These cells are characterized by the expres-
sion of c-Kit and include the CML LSK population, previously
suggested to possess all LIC activity (Neering et al., 2007; Rey-
naud et al., 2011). When we subdivided the c-Myc-expressing
population using the c-MyceGFP reporter, we were able to trans-
plant disease only using the c-MyceGFP LSK fraction suggesting
that although LIC activity lies within the c-Myc-expressing frac-
tion, c-Myc protein expression is not sufficient to guarantee
leukemia-initiating properties. This is an intriguing distinction
between normal and leukemic hematopoiesis as we showed
that normal c-MyceGFP LSK cells are multipotential progenitors
but not bona fide HSC (Reavie et al., 2010).
We have shown that Fbw7 is required for normal hematopoi-
esis, because its deletion leads to progressive adult stem cell
exhaustion. This would suggest that inhibition of Fbw7 activity
is not an ideal therapeutic target in leukemia. However, the
response of normal and malignant stem and progenitor cells to
the deletion of Fbw7 is vastly distinct. Putative LIC respond
acutely, as Fbw7 deletion leads to rapid (<2 weeks) loss of cell
numbers and activity, whereas the response of normal HSC is
delayed and there are no significant changes in the number of
HSC cells until 10–12 weeks post Fbw7 deletion (Matsuoka
et al., 2008; Thompson et al., 2008) (data not shown). We believe
that this differential response to Fbw7 deletion can be explained
Cancer Cell
Fbw7 Controls CML-Initiating Cell Maintenanceby the significantly higher levels of c-Myc protein in the Bcr-Abl-
expressing LIC. These data suggest that it should be possible to
define a therapeutic window altering either the concentration of
the inhibitor or the length of the treatment. Drug combination
could be another therapeutic avenue, especially as TKI fail
to target CML LIC. Indeed, Nakayama and colleagues have
demonstrated that Fbw7 inhibition can be used in combina-
tion with other established CML treatments, including imatinib,
to achieve efficient targeting of CML-initiating cells (Takeishi
et al., 2013), both in animal models and primary human disease.
At this point, no Fbw7 inhibitors have been identified. However,
recent studies suggested that a small molecule targeting Fbw7
is a feasible approach. Tyers and collegues have recently identi-
fied a biplanar dicarboxylic acid compound as an inhibitor of
substrate recognition by the yeast Fbw7 ortholog (Cdc4) (Agha-
jan et al., 2010; Orlicky et al., 2010). Moreover, as Fbw7-medi-
ated c-Myc recognition is induced by the priming phosphoryla-
tion of c-MycThr58 by GSK3, GSK3 inhibitors could also be
used to target Fbw7 function and c-Myc stability. Such inhibitors
have been developed and their efficacy in vivo was tested using
MLL-induced models of AML (Wang et al., 2008). These GSK3
inhibitors are currently in Phase II clinical trials for the treatment
of Alzheimer disease (Martinez et al., 2011), opening the way for
their future use for the treatment of CML in combination with
TKIs. Finally, because c-Myc activity is a driver of distinct tumor
types, it is conceivable that Fbw7 inhibitors could be promising
therapeutic tools in a wide range of blood and solid tumors.
EXPERIMENTAL PROCEDURES
Animals
Fbw7floxmice were previously published (Thompson et al., 2008).Mycfloxmice
were a kind gift from F. Alt (de Alboran et al., 2001), and MyceGFP mice were
a kind gift from Dr. Barry Sleckman (Huang et al., 2008). Interferon-a-inducible
Mx1cre, p53 germline knockout, and C57Bl6 recipient mice were purchased
from Jackson Laboratories. All mice were housed in a pathogen-free animal
facility at the NYU School of Medicine. All animal procedures were approved
by Institutional Animal Care and Use Committee of the NYU School of Medi-
cine and carried out in compliance with NIH guidelines.
Generation and Analysis of CML Animals
LSK were isolated from 4- to 6-week-old mice using the mouse hemato-
poietic progenitor enrichment kit (Stem Cell Technologies) per manufacturer’s
protocol and stained with a lineage cocktail, c-Kit, and Sca-1 antibodies
followed by FACS purification. LSK were cells were infected with Bcr-
Abl-NGFR or Bcr-Abl-GFP retrovirus (Wertheim et al., 2002) and spun at
2500 rpm for 90 min at 30C. Forty-eight to 72 hr posttransfection,
20,000–40,000 Lin Bcr-Abl+ LSKs were transplanted intravenously into
lethally irradiated recipient mice with 2–5 3 105 support BM cells. For donor
cells deleted posttransplantation, deletion was initiated on day 7 posttrans-
plantation with three injections of poly(I:C) (Amsersham) at a concentration
of 5 mg/g of body weight, and disease was monitored by flow cytometry.
Further details of culture and analysis are provided in the Supplemental Exper-
imental Procedures.
Analysis and Culture of Human CML Samples
Primary patient samples were obtained with informed consent from all donors
in accordance with the Declaration of Helsinki and studies were approved
by the Institutional Review Boards at NYU Medical Center, and Memorial
Sloan-Kettering Cancer Center. UCB or patient BM CD34+ cells were isolated
using CD34+ selection kit following manufacturer’s instructions (Stem Cell
Technologies). Cells were cultured in Stemspan (Stem Cell Technologies),
supplemented with 50 ng/ml SCF, 50 ng/ml Flt3L, and 100 ng/ml Tpo for24 hr followed by lentiviral transduction. Further details of culture and analysis
are provided in the Supplemental Experimental Procedures.
FACS Analysis
All antibodies used for FACS analysis were procured from e-Bioscience.
Specifically, the antibodies we used were as follows: c-Kit (2B8), Sca-1 (D7),
Mac-1 (M1/70), Gr-1 (RB6-8C5), NK1.1 (PK136), TER-119, CD3 (145-2C11),
CD19 (1D3), IL7R (RAM34), CD4 (RM4-5), CD8 (53-6.7), CD271 (NGFR), and
(ME20.4). BM lineage antibody cocktail includes the following: Mac-1, Gr-1,
NK1.1, TER-119, CD4, CD8, IL7R, and CD19. Apoptosis was detected using
an Annexiv-V PE-conjugated detection kit (BD PharMingen) along with
7-AAD following manufacturer’s protocol. For intracellular c-Myc staining,
cells were stained with anti-CD34 (BD PharMingen), washed, fixed, and per-
meabilized using BD cytofix/cytoperm kit following manufacturer’s protocol.
Stainings were performed with rabbit anti-c-Myc (Cell Signaling) followed by
goat anti-rabbit Alexa Fluor 647 (Invitrogen).
Quantitative Real-Time PCR
Total RNA was harvested from cells using the QIAGEN RNeasy Kit (QIAGEN,
Germany). RNA was quantified by absorbance at A260 nm and 2 mg of total
RNA used for cDNA synthesis using Superscript III first strand synthesis kit
(Invitrogen). qRT-PCR was carried out using SYBR green universal mix PCR
reaction buffer (Roche) using an Roche lightcycler 480 II (Roche). All signals
are normalized to levels of Gapdh.
Statistical Analysis
All statistical analyses were performed using an unpaired two-tailed Student’s
t test, unless otherwise specified.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.01.025.
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